Biologics (Monoclonal Antibodies) CDMOs in Asia-Pacific
24 published
24 published CDMOs match Biologics (Monoclonal Antibodies) in Asia-Pacific.
Locations in this set include United States, China, India, Japan, Germany, and United Kingdom.
Capabilities that show up most often in this set: CMC Analytical Development, Process Development, Formulation Development, Monoclonal Antibody (mAb) Manufacturing, and Quality Control Testing.
Matching companies
Vetter PharmaIndependent CDMO specialist in aseptic fill-finish, drug product development, analytical services, and combination product assembly with 76 years of experience and 7,300+ employees globally.
WuXi VaccinesGlobal CDMO specializing in end-to-end vaccine and prophylactic antibody development and manufacturing across mammalian, viral, and microbial platforms with GMP-certified facilities and over 550 million doses delivered.
WuXi XDCWuXi XDC is a leading CRDMO offering integrated discovery, development, and cGMP manufacturing services for antibody drug conjugates (ADCs) and bioconjugates, with proximately located facilities that reduce development timelines and costs.
Yapan BioYapan Bio provides integrated process development, characterization, and GMP manufacturing for vaccines, monoclonal antibodies, gene therapy, and viral vector-based biologics, with capabilities up to 1000L bioreactor scale and BSL-2+ containment.
Markdown mirror: /modalities/biologics-monoclonal-antibodies/apac.md